Why False Positives Are Built Into Screening

A false positive is an abnormal result in someone who does not have the condition. These are expected outputs of a working programme rather than evidence of a broken test.

Testing healthy populations changes the arithmetic

Screening is applied to people without symptoms, most of whom do not have the condition being sought.

Even a small error rate applied to a very large healthy group produces a substantial number of abnormal results, because the healthy group is so much bigger.

The number of true cases is limited by how common the disease is. The number of false alarms is limited only by how many people are tested.

Tests measure proxies rather than disease

Few screening tests detect disease directly. They measure something associated with it, such as a protein level, a shadow on an image or a change in tissue appearance.

Those proxies have other causes. Inflammation, infection, benign growths, recent activity and ordinary anatomical variation can all move a marker.

The test cannot distinguish between the causes of the signal. That separation is precisely what the follow-up investigation is for.

The follow-up is where harm is concentrated

A false alarm is not costless. It generates anxiety that persists even after the all-clear, and it triggers further tests.

Those tests carry their own risks, from radiation exposure to bleeding, infection or complications of a biopsy.

They also consume time and money, both for the health system and for the individual taking time away from work.

Repeat rounds compound the chance

Screening is usually repeated at intervals, and the chance of at least one false alarm accumulates over a lifetime of participation.

Over many rounds, a meaningful proportion of participants will experience at least one abnormal result requiring follow-up.

This cumulative figure rarely appears in the discussion of a single test, though it is the number most relevant to someone deciding whether to take part.

Why the trade-off is still usually worth it

Programmes are evaluated on whether the reduction in serious outcomes outweighs the total burden of false alarms and unnecessary procedures.

Where that balance is unfavourable, screening is not offered, which is why many plausible-sounding tests are deliberately not used at population level.

Deciding whether to participate is a personal judgement informed by individual risk, and the person best placed to frame it is a clinician who knows the history.